Welcome to our dedicated page for 89Bio news (Ticker: ETNB), a resource for investors and traders seeking the latest updates and insights on 89Bio stock.
News for 89bio, Inc. (ETNB) centers on its role as a clinical-stage biopharmaceutical company developing therapies for liver and cardiometabolic diseases, as well as its corporate transition following its acquisition by Roche. Company press releases and SEC reports highlight pegozafermin, a fibroblast growth factor 21 (FGF21) analog engineered with glycoPEGylated technology, as its lead product candidate in Phase 3 development for metabolic dysfunction-associated steatohepatitis (MASH) with advanced fibrosis and severe hypertriglyceridemia (SHTG).
Visitors to this ETNB news page can review historical announcements about 89bio’s clinical programs, including updates on the ENLIGHTEN-Fibrosis and ENLIGHTEN-Cirrhosis Phase 3 trials in MASH and the ENTRUST Phase 3 trial in SHTG. Releases describe trial designs, planned topline data timing, and the company’s expectations regarding potential regulatory pathways, as well as operational items such as construction of a commercial-scale production facility for pegozafermin.
The news flow also covers corporate and capital markets activity. This includes inducement stock option grants under Nasdaq Listing Rule 5635(c)(4), participation in major healthcare and biopharma investor conferences, and quarterly financial updates that discuss research and development spending and general and administrative expenses in the context of advancing the Phase 3 programs.
A key development in the ETNB news record is the announcement of an Agreement and Plan of Merger with Roche Holdings, Inc., followed by the commencement and completion of a tender offer. Related communications describe the cash consideration, the structure of non-tradeable contingent value rights (CVRs) tied to pegozafermin milestones, and the subsequent delisting of ETNB from The Nasdaq Global Market as 89bio became a wholly owned subsidiary of Roche. Investors and researchers can use this page as an archive of 89bio’s historical news, from clinical milestones to the closing of the Roche transaction.
89bio, a clinical-stage biopharmaceutical company (Nasdaq: ETNB), has announced a public offering of 2,200,000 shares of its common stock, with an option for underwriters to purchase an additional 330,000 shares. Proceeds will support the acceleration of its BIO89-100 programs for treating nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). The offering is contingent on market conditions, and full details will be available in the prospectus.
89bio, Inc. (Nasdaq: ETNB) announced its Q1 2020 financial results, reporting a net loss of $10.5 million compared to $4.4 million in Q1 2019. The increase in loss is linked to higher R&D expenses of $7.8 million, up from $4.3 million a year earlier, and G&A expenses rising to $2.9 million from $0.5 million. The company closed enrollment in its Phase 1b/2a NASH trial with 98% of patients enrolled, expecting topline results in 2H20. Additionally, the FDA cleared its IND application for BIO89-100 targeting severe hypertriglyceridemia, paving the way for a Phase 2 trial when conditions allow.
89bio, a clinical-stage biopharmaceutical company focused on liver and cardio-metabolic diseases, announces CEO Rohan Palekar’s participation in upcoming conferences. He will speak at the BofA Securities 2020 Virtual Global Healthcare Conference on May 14, 2020, at 11:00 AM ET and at the RBC Capital Markets 2020 Global Healthcare Virtual Conference on May 20, 2020, at 3:05 PM ET. The presentations will be accessible live and as an archived webcast on the company’s website, enhancing investor engagement. The lead product candidate, BIO89-100, targets NASH treatment.